Pharmaceutical

Astellas and Evopoint sign ADC licensing deal

Astellas Pharma has signed an exclusive licensing agreement with Evopoint Biosciences for XNW27011, a CLDN18.2-targeting clinical-stage ADC.

Jun 1, 2025 - 06:00
Astellas and Evopoint sign ADC licensing deal
Astellas Pharma has signed an exclusive licensing agreement with Evopoint Biosciences for XNW27011, a CLDN18.2-targeting clinical-stage ADC.
Read the original article

Tags:

Previous Article

FDA rejects Stealth Bio’s Barth syndrome treatment after 16.5-month review

Next Article

Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Transforming manufacturing and packaging at PHARMAP 2025

Transforming manufacturing and packaging at PHARMAP 2025

Feb 25, 2025

Opinion: Listen: The true costs of mediocre insurance plans for medical students

Opinion: Listen: The true costs of mediocre insurance p...

Nov 15, 2023

Opinion: Listen: Why long Covid might predate the pandemic

Opinion: Listen: Why long Covid might predate the pandemic

Oct 18, 2023